精神药理学的未来发展道路
Future paths in psychopharmacology .
作者信息
Thibaut Florence
机构信息
Author affiliations: University Hospital Cochin (site Tarnier), Faculty of Medicine Paris Descartes (University Sorbonne-Paris Cité), INSERM U1266, Institute of Psychiatry and Neuroscience, Paris, France. Address for correspondence:
出版信息
Dialogues Clin Neurosci. 2019;21(2):115-116. doi: 10.31887/DCNS.2019.21.2/fthibaut.
Abstract
Drug development in psychiatry is gradually moving from serendipity to personalized medicine. Some promising paths will be reviewed in this issue. .
摘要
精神病学领域的药物研发正逐渐从偶然发现转向个性化医疗。本期将对一些有前景的途径进行综述。
相似文献
1
Future paths in psychopharmacology
.
Dialogues Clin Neurosci. 2019;21(2):115-116. doi: 10.31887/DCNS.2019.21.2/fthibaut.
2
Biographies.
Acta Psychiatr Scand. 2005 Jul;112(1):82-4. doi: 10.1111/j.1600-0447.2005.00577.x.
3
Incentive motivation, conditioning, stress, and neuropsychiatric disorders: a tribute to Jane Stewart.
Biol Psychiatry. 2009 May 15;65(10):827-8. doi: 10.1016/j.biopsych.2008.12.012.
4
The impact of psychopharmacology on contemporary psychiatry.
Can J Psychiatry. 2014 Aug;59(8):401-5. doi: 10.1177/070674371405900801.
5
Preface: Pediatric and adolescent psychopharmacology: the past, the present, and the future.
Pediatr Clin North Am. 2011 Feb;58(1):xv-xxiv. doi: 10.1016/j.pcl.2010.11.005.
6
[Drug safety in clinical practice--part 2: psychopharmacological treatment].
Fortschr Neurol Psychiatr. 2013 Dec;81(12):715-27; quiz 728-9. doi: 10.1055/s-0033-1355883. Epub 2013 Dec 4.
7
Special issue: Incentive Motivation, Conditioning, Stress, and Neuropsychiatric Disorders: A Tribute to Jane Stewart.
Biol Psychiatry. 2009 May 15;65(10):827-913.
8
[Psychopharmacology as the 20th century turns to the 21st].
Rev Med Suisse Romande. 2000 Feb;120(2):95-7.
9
Perspectives of neuroscience in psychiatry.
Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S149-51. doi: 10.1055/s-2003-45122.
10
Psychopharmacology and the future of personalized treatment.
Depress Anxiety. 2014 Nov;31(11):906-8. doi: 10.1002/da.22303.
本文引用的文献
1
Current status and future prospects for the development of substance abuse vaccines.
Expert Rev Vaccines. 2017 Nov;16(11):1067-1077. doi: 10.1080/14760584.2017.1378577. Epub 2017 Sep 20.
2
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms.
World J Biol Psychiatry. 2017 Aug;18(5):330-356. doi: 10.1080/15622975.2016.1224929. Epub 2016 Oct 26.
3
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.
World J Biol Psychiatry. 2016 Sep;17(6):406-28. doi: 10.1080/15622975.2016.1183043. Epub 2016 Jun 17.
4
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology.
World J Biol Psychiatry. 2015;16(5):280-90. doi: 10.3109/15622975.2015.1050061.
Zotero 插件